trending Market Intelligence /marketintelligence/en/news-insights/trending/ixrvuaoh4usfwcmebut2yw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Novartis to fund oral skin cancer drug

Street Talk Episode 51 - Goldman Talks Libor Transition, Recent SOFR Volatility

#ChangePays: Although Still Underrepresented, Women in the C-Suite are Driving Profitability

Cable Nets For Kids Enjoy Wide Carriage On Skinny Bundles


Power Forecast Briefing: Fleet Transformation, Under-Powered Markets, and Green Energy in 2018

Novartis to fund oral skin cancer drug

Ligand Pharmaceuticals Inc. is partnering with Novartis AG to develop a liquid formulation of Trametinib using its Captisol technology.

Trametinib is used to treat a certain type of skin cancer with Captisol designed to optimize the solubility and stability of drugs.

Novartis will fund the program in exchange for commercialization rights. Ligand will receive an undisclosed license fee as well as royalties on future sales as a result of the agreement.